Future research should systematically compare the effects of different agonists, antagonists, and selective AhR modulators (sAhRMs), aiming to screen or design targeted AhR therapies for metabolic diseases that can harness its benefits while mitigating its detrimental effects. This evidence concerns the gene AHR and metabolic disease.